Table 2. Efficacy of first-line chemotherapy in RM/NPC.

Regimen	ORR (95% CI)	DCR (95% CI)	6-month PFS rate (95% CI)	1-year OS rate (95% CI)
FP	0.52 (0.38–0.65)	0.87 (0.82–0.92)	0.58 (0.42–0.73)	0.63 (0.57–0.69)
GP	0.54 (0.45–0.63)	0.85 (0.71–0.93)	0.69 (0.60–0.78)	0.71 (0.61–0.80)
TP	0.60 (0.48–0.72)	0.92 (0.86–0.98)	0.50 (0.28–0.73)	0.79 (0.65–0.92)
Triplet combination regimen	0.74 (0.62–0.87)†	0.91 (0.87–0.95)†	0.83 (0.75–0.91)†	0.74 (0.61–0.87)

^†, these pooled data derived from studies using WHO criteria as efficacy evaluation tool. R/M NPC, recurrent or metastatic nasopharyngeal carcinoma; FP, 5-fluorouracil plus platinum; GP, Gemcitabine plus platinum; TP, taxanes plus platinum; ORR, objective response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival.